Hopace MT Tablets contain Ramipril 5 mg and Metoprolol Succinate 50 mg.

Hopace MT Tablets combine the benefits of Ramipril, a long-acting angiotensin-converting enzyme (ACE) inhibitor, and Metoprolol Succinate, a cardioselective beta1-adrenergic receptor blocker. This dual-action combination provides effective once-daily blood pressure control by reducing angiotensin II-mediated vasoconstriction, decreasing aldosterone secretion, lowering heart rate, and reducing cardiac workload. The complementary mechanisms help improve cardiovascular outcomes in patients with essential hypertension.

Hopace MT Tablets are indicated for the treatment of essential hypertension.

Ramipril is an angiotensin-converting enzyme (ACE) inhibitor that blocks the conversion of angiotensin I to angiotensin II, leading to reduced vasoconstriction, decreased aldosterone secretion, and lowering of blood pressure. Metoprolol Succinate is a beta1-selective (cardioselective) adrenergic receptor blocker that lowers blood pressure by reducing heart rate, cardiac output, exercise-induced systolic blood pressure, isoproterenol-induced tachycardia, and reflex orthostatic tachycardia. Together, these agents reduce cardiac workload and promote effective blood pressure control.

The recommended dosage is one tablet orally once daily, or as directed by the physician.

Hopace MT Tablets are contraindicated in patients with known hypersensitivity to Ramipril, Metoprolol, ACE inhibitors, or any component of the formulation, history of hereditary or idiopathic angioedema, severe bradycardia, heart block greater than first degree, cardiogenic shock, decompensated cardiac failure, sick sinus syndrome (unless a permanent pacemaker is in place), and hemodynamically unstable conditions.